Suggested remit: To evaluate the benefits and costs of setmelanotide within its marketing authorisation for treating obesity caused by leptin receptor (LEPR) deficiency or pro-opiomelanocortin (POMC) deficiency for national commissioning by NHS England.
Status In progress
Process HST
ID number 3764

Provisional Schedule

Committee meeting: 1 06 October 2021
Expected publication 23 March 2022

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter


Companies sponsors Rhythm Pharmaceuticals (setmelanotide)
Others Department of Endocrinology, University Hospital Birmingham Foundation Trust
  Department of Health and Social Care
  Great Ormond Street Hospital Metabolic Unit
  National Hospital for Neurology and Neurosurgery Charles Dent Metabolic Unit
  NHS England
  Salford Royal NHS Foundation Trust Mark Holland Metabolic Unit
  Willink Unit, Genetic Medicine, Central Manchester Foundation Trust
Patient carer groups BEAT
  British Obesity Society
  British Obesity Surgery Patients Association
  Genetic Alliance UK
  Healthier Weight Centres
  Muslim Council of Britain
  National Centre for Eating Disorders
  National Obesity Forum
  Obesity Health Alliance
  Obesity UK
  Overeaters Anonymous
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Weight Concern
Professional groups Association for the Study of Obesity
  British Association of Endocrine and Thyroid Surgeons
  British Geriatrics Society
  British Nutrition Foundation
  British Obesity Surgery Society
  Nutrition Society
  Obesity Management Association
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Paediatrics & Child Health
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for Endocrinology
  UK Clinical Pharmacy Association
  UK Health Forum


Associated public health groups Faculty of Public Health Medicine
  Public Health England
  Public Health Wales
Comparator companies Alissa Healthcare Research (orlistat)
  Almus Pharmaceuticals (orlistat)
  Cheplapharm Arzneimittel (orlistat)
  Crescent Pharma (orlistat)
  GlaxoSmithKline Consumer Healthcare (orlistat)
  Teva UK (orlistat)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Inherited Metabolic and Lysosomal Disease Service, Cardiff and Vale UHB
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  National Services Division
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Metabolic & Endocrine Disorders Group
  Cochrane Public Health Group
  Genomics England
  MRC Clinical Trials Unit, UCL
  National Institute for Health Research
  Wellcome-MRC Institute of Metabolic Science, Addenbrookes


Key events during the development of the guidance:

Date Update
10 May 2021 Invitation to participate
07 May 2021 In progress. In progress
31 July 2020 (14:00) Scoping workshop (Manchester)
08 June 2020 - 06 July 2020 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance